<HashMap><database>ecrin-mdr-crc</database><scores/><additional><omics_type>Clinical</omics_type><study_start_year>2020</study_start_year><data_sharing_plan>IPD Sharing (as of September 2023): Yes
Description: Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.</data_sharing_plan><condition>Stage II Breast Cancer</condition><condition>Stage I Prostate Cancer</condition><condition>Colorectal Cancer</condition><condition>Stage II Colorectal Cancer</condition><condition>Stage I Breast Cancer</condition><condition>Breast Neoplasms</condition><condition>Breast Cancer</condition><condition>Stage I Colorectal Cancer</condition><condition>Stage III Prostate Cancer</condition><condition>Stage III Colorectal Cancer</condition><condition>Prostatic Neoplasms</condition><condition>Colorectal Neoplasms</condition><condition>Prostate Cancer</condition><condition>Stage II Prostate Cancer</condition><condition>Stage III Breast Cancer</condition><disease>Stage Ii Prostate Cancer</disease><disease>Stage I Prostate Cancer</disease><disease>Stage Iii Prostate Cancer</disease><disease>Colorectal Cancer</disease><disease>Stage Iii Colorectal Cancer</disease><disease>Stage I Breast Cancer</disease><disease>Breast Neoplasms</disease><disease>Breast Cancer</disease><disease>Stage I Colorectal Cancer</disease><disease>Stage Ii Colorectal Cancer</disease><disease>Prostatic Neoplasms</disease><disease>Stage Iii Breast Cancer</disease><disease>Stage Ii Breast Cancer</disease><disease>Colorectal Neoplasms</disease><disease>Prostate Cancer</disease><study_type>Interventional</study_type><full_dataset_link>https://newmdr.ecrin.org/Study/2354679</full_dataset_link><location>United States</location><study_start_month>10</study_start_month><keyword>CtDNA</keyword><keyword>Exercise</keyword><keyword>Memorial Sloan Kettering Cancer Center</keyword><keyword>20-378</keyword><repository>ECRIN MDR</repository><study_status>Recruiting</study_status></additional><is_claimable>false</is_claimable><name>Researching the Effect of Exercise on Cancer</name><description>Researchers think that exercise may be able to prevent cancer from coming back by lowering ctDNA levels. The purpose of this study is to explore how aerobic exercise (exercise that stimulates and strengthens the heart and lungs and improves the body’s use of oxygen) can reduce the level of ctDNA found in the blood. During the study, the highest level of exercise that is practical, is safe, and has positive effects on the body that may prevent the return of cancer (including a decrease in ctDNA levels) will be found. Each level of exercise tested will be a certain number of minutes each week. Once the best level of exercise is found, it will be tested further in a new group of participants. All participants in this study will have been previously treated for breast, prostate, or colorectal cancer.</description><dates><creation>2020-10-15</creation></dates><accession>2354679</accession><cross_references><ClinicalTrials___gov>NCT04589468</ClinicalTrials___gov></cross_references></HashMap>